Q-omics provides the consensus-scored STUM profile across patient tissues and cancer cell-line models. STUM expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, STUM is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, STUM RNA expression shows 16,783 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BLCA, and THYM as cancer lineages where STUM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STUM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STUM survival associations across molecular data types. STUM RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STUM RNA expression–survival associations across cancer types. High STUM expression shows unfavorable associations in UVM and BLCA, but favorable associations in HNSC, LGG, KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for STUM RNA expression.
This table summarizes STUM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STUM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STUM shows lower tumor expression in BLCA, COAD, THCA, KIRC, HNSC and KIRP. The BLCA box plot shows higher STUM RNA expression in normal versus tumor tissue (log2 FC = −4.045, t-test p < 0.001).
This table shows molecular features associated with STUM in patient tissues and cancer cell lines. In patient samples, STUM shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STUM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
